Skip to main content

Par Pacific Holdings Reports Third Quarter 2025 Results

HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the quarter ended September 30, 2025.Net Income of $262.6 million, or $5.16 per diluted share Adjusted Net Income of $302.6 million, or $5.95 per diluted share Adjusted EBITDA of $372.5 million Small refinery exemption (“SRE”) impact of $195.9 million in Adjusted Net Income and $202.6 million in Adjusted EBITDA Repurchased $16.4 million of common stock Closed Hawaii Renewables joint venture in October and received cash proceeds of $100 millionPar Pacific reported net income of $262.6 million, or $5.16 per diluted share, for the quarter ended September 30, 2025, compared to $7.5 million, or $0.13 per diluted share, for the same quarter in 2024. Third quarter 2025 Adjusted...

Continue reading

THEON announces a new order for Night Vision Goggles worth over €100 million, increasing backlog to c.€700 million

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)4 November 2025 – Theon International Plc (THEON) secured a new order worth over €100 million from a European NATO member state as part of the €300 million framework agreement announced on 17 October. This first tranche of this agreement requires the delivery of several thousands Night Vision Goggles (NVGs), monoculars and binoculars. The deliveries are evenly scheduled for 2026, 2027 and 2028. Additional orders are expected in the short and mid-term under the same agreement, not only for NVGs but also for Thermal clip-ons IRIS-C. In light of recent announcements, year-to-date order intake has exceeded €370 million, with additional new options amounting to €441 million. Consequently, as of 4 November, the soft backlog – excluding orders invoiced in October – stands at...

Continue reading

Publishing of Eimskip’s third quarter 2025 results

Eimskipafélag Íslands hf. will publish its third quarter 2025 results after market closing on Tuesday 11 November.  Investor meeting on 12 November 2025 Eimskip invites investors and market participants to a meeting where Vilhelm Thorsteinsson, CEO and Rósa Guðmundsdóttir, CFO, will present the results. The meeting will be held on Wednesday 12 November at 8:30 GMT at the Company’s headquarters, Sundabakki 2, second floor. The meeting will also be webcasted live in Icelandic on www.eimskip.com/investors. Investors can send questions before the meeting to the email investors@eimskip.com. Documents and a recording of the meeting will be available at the Company’s investor relations website, www.eimskip.is/investors. For further information please contact Guðbjörg Birna Björnsdóttir, Head of Treasury and Investor Relations, tel: +354 844 4752,...

Continue reading

NNIT A/S: On-track performance with doubled profitability

Q3 2025 key highlightsWhile business was still being negatively impacted by macroeconomic and geopolitical uncertainty, there was an uplift in financial performance in the third quarter. Group operating profit excluding special items more than doubled at DKK 35.6m, corresponding to a margin of 8.2% against 3.9% in the third quarter of 2024. The step-change in margin development compared with last quarter and last year was driven by more efficient operations in terms of improving utilization and the effect from cost reducing initiatives carried out during 2024 and the first half of 2025. NNIT continued the momentum from late Q2 into Q3 with a solid order entry, which is a leading indicator into the fourth quarter and full-year 2026. Revenue amounted to DKK 431.6m in Q3 2025, equal to a negative revenue growth of 2.9% and organic growth...

Continue reading

Invitation to the webinar on Eesti Energia’s Q3 2025 financial results

Eesti Energia will publish its Q3 2025 financial results and interim report on 7 November. The investor call to present the results will take place on 7 November at 11:00 London time, 12:00 Frankfurt time, and 13:00 Tallinn time. The conference call will be held in English only. To participate, please join via the following link. A Q&A session will follow the presentation. As the webinar time is limited, we encourage participants to submit their questions in advance to investor@enefit.com The report and the investor call presentation will be made available in the morning of 7 November on the Eesti Energia Investor Relations website. The recording and transcript of the call will be published on the same page afterwards. Further information:Danel FreibergHead of Treasury and Financial Risk ManagementEesti Energia ASTel: +372 5594 3838Email:...

Continue reading

Q3 2025: Financial guidance for 2025 narrowed

Announcement no. 13-2025 4 November 2025 Lasse Ingemann Brodt, Group CEO of North Media, on the Group’s performance in Q3 2025:“Our Q3 2025 performance reflected a slightly lower activity level. We saw slight revenue declines in both Last Mile and Digital Services. We generated operating profit growth in Digital Services, where we reduced the losses in Dayli and Bekey by completing development projects and enhancing the efficiency of key processes. In October, we reached an important milestone in the integration of SDR into North Media as the roll-out of automated packing of printed matter for the Swedish market has now been fully completed. This creates more uniform processes across the distribution areas in Sweden and is expected to lead to costs reductions in the long term.        Financial highlights:DKKm Q3 Q3 YTD  2025 2024 2025 2024Revenue 286.4 299.4 939.2 961.4EBITDA 12.1 19.4 71.1 120.9EBIT -1.7 3.0 29.3 59.2EBIT...

Continue reading

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months–  – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR and mPFS 9.1 months in histology selective cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity – – $225 million in gross proceeds from October 2025 financing extends cash runway into 2028 – BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. “We are wrapping up 2025 with significant momentum,...

Continue reading

Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights

—  Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7%  — Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth — First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1% — First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period — Approximately 667,00 pulse treatments administered since commercialization — Company expects to achieve net profitability in 2025 SAN CLEMENTE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the third quarter and first nine...

Continue reading

Exagen Inc. Reports Strong Q3 2025 Results

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.    Three Months Ended September 30,   Nine Months Ended September 30,    2025   2024   2025   2024(Unaudited, in thousands, except ASP data)    Revenue   $ 17,244     $ 12,507     $ 49,944     $ 41,986  Gross margin     58.4 %     55.8 %     59.3 %     58.7 %Operating expenses   $ 13,175     $ 11,644     $ 38,688     $ 34,888  Operating loss   $ (3,100 )   $ (4,663 )   $ (9,095 )   $ (10,253 )Net loss   $ (7,087 )   $ (5,028 )   $ (15,278 )   $ (11,354 )Adjusted EBITDA   $ (1,895 )   $ (4,024 )   $ (6,124 )   $ (7,614 )Cash and cash equivalents   $ 35,652     $ 22,035     $ 35,652     $ 22,035  Trailing-twelve-month...

Continue reading

Camposol Holding PLC’s Invitation to the Third Quarter 2025 Financial Results Presentation

Camposol Holding PLC will announce its preliminary financial results for the third quarter of 2025 on Wednesday, November 26, 2025, at 9:00 a.m. Eastern Time (ET). In connection with this release, Ricardo Naranjo Fernandez, CEO, and Jossue Yesquen Lihim, IRO, will host a conference call presentation and Q&A session. To register and participate in the conference call please use the following link: https://register-conf.media-server.com/register/BIcd23eb97c328417c99dcf2bfc1fd4b33 Participants are advised to log in to the conference call service and check their audio and system settings a few minutes before the conference call begins. To access the webcast presentation associated with the conference call, please click on the following link: https://edge.media-server.com/mmc/p/i79eb45v If you are unable to participate in the conference...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.